Stryker Corporation

SYK Healthcare Medical Devices

Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.42%, EPS grew 43.1%, free cash flow grew 14.1% and total debt fell 9.88%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.

294.66 1.43 +0.49%
Market cap
$112.5B
P/E
30.3×
Fwd P/E
24.1×
Dividend yield
1.19%
F-score
5/9
Altman Z
4.81
Beneish M
−2.62
Dividend safety
82/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

14.04% 15.08% 15.20% 16.51%
Piotroski F-Score
4 5 7 7
ROA
6.48% 7.15% 7.23% 7.91%
ROIC
6.54% 8.94% 8.97% 9.76%
Return on Tangible Assets
29.34% 29.95% 30.59% 31.89%
Average Days of Receivables
54.54 58.70 51.58 52.88
Free Cash Flow per Share
11.08 11.21 11.94 12.26
Free Cash Flow
4,238.00 4,283.00 4,571.00 4,702.00
Capital Expenditures
(594.00) (761.00) (804.00) (823.00)
Other line items
Cash ROIC
10.16% 10.11% 11.24% 11.09%
Accounts Receivable Turnover
6.61 6.26 6.71 6.75
Accounts Payable Turnover
6.19 5.20 5.98 5.83
Inventory Turnover
1.65 1.80 1.74 1.67
Average Days of Payables
62.35 72.55 63.58 67.08
Days of Inventory on Hand
223.49 214.14 216.43 222.69
Tax Rate
(0.12) (0.28) (0.27) (0.28)
Research and Development Expense of Revenue
6.48% 6.46% 6.45% 6.42%
Selling, General and Administrative Expense of Revenue
35.06% 34.44% 34.16% 33.99%
Share Based Compensation of Revenue
0.98% 0.97% 0.97% 0.97%
Interest Coverage
— 7.86 6.61 7.29
Operating CF/Net income
1.64 1.55 1.61 1.48
Depreciation/Fixed assets
0.31 0.31 0.31 0.31
Capex/Depreciation
(0.52) (0.64) (0.66) (0.67)
Revenue per Share
63.76 65.71 66.00 67.37
Operating CF per Share
12.64 13.20 14.04 14.41
Capex per Share
(1.55) (1.99) (2.10) (2.15)
Capex to Sales
0.02 0.03 0.03 0.03

Fold the line items

Columns are period end dates